Pursuing A New Paradigm in Inclusive Research
The significance of clinical trials to provide more robust data, ultimately leading to more effective medicines for patients who need them.
AscellaHealth
End-to-End Solutions Optimize Rare Disease Clinical Trials and Product Commercialization
Pharmaceutical manufacturers rely upon AscellaHealth as a single resource for managing all phases of rare disease clinical trials.
A Look at von Willebrand Disease
An inherited blood clotting disorder caused by either a deficiency or a dysfunction of the von Willebrand factor (vWf) protein.
HUB & Patient Support Solutions Complement Pre-Commercialization Services
AscellaHealth’s expanded HUB/ Patient Support Services for Life Sciences manufacturers are recognized as the best-in-class outsourced solutions for successful medication access, compliance and persistency and enhanced outcomes.
Re-Think. Re-Consider. Re-Calibrate.
2023 Go-to-Market Strategies for Launching Specialty Drugs, Gene & Cell Therapies
Something for Everyone at Rare Disease Week on Capitol Hill
Rare Disease Week on Capitol Hill, February 28th through March 2nd, 2023.
AscellaHealth EU
AscellaHealth Specialty Pharmacy Distribution & Market Access Webinar Highlights
Experts provide in-depth insights on commercialization strategy, distribution models and demonstrating therapeutic value of Rare Disease & Gene/Cell therapies for patients, payers, and providers.
AscellaHealth Family of Companies Announces Founding Sponsorship: Gene Therapy and Specialty Pharmacy Awareness Month
September 2022: Join us in recognizing industry innovations
Global Genes: Improving the Path to Diagnosis and Treatment for Individuals Living with Rare Disease
With more than 10,000 rare diseases, Global Genes focuses on advancing innovation and overcoming challenges.
Patient-First Approach: Initial Step in Addressing Nation’s Health Inequities
Removing barriers to reach Health equity.
Changing the Face of Market Access and Commercialization
AscellaHealth Family of Companies brings integrated, customized approach for specialty drugs underscoring value of effective payer strategies.
Optimizing Treatment for Rare Genetic Condition: Cushing’s Syndrome
Cushing’s syndrome, a rare endocrine disorder and FDA approved treatments.
Update on Gene Therapy and Genome-Editing for Rare Diseases
There’s some upbeat news in gene therapy and genome-editing treatments.
Pharmaceutical Companies Turn to AscellaHealth Family of Companies for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services
Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.
Foundation for the National Institutes of Health Accelerates Biomedical Research and Strategies Around the World
FNIH manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH).
Patient Services and Hub Solutions for Life Sciences: Ensuring Specialty Product Access and Market Entry, Optimizing Outcomes for Rare Disease Patients
The rare disease community is gaining attention around the world, shining a light on the challenges and barriers to accessing care.
Optimizing Treatment for Rare Genetic Condition Hereditary Angioedema
Hereditary Angioedema (HAE) is a rare, unpredictable and potentially life-threatening genetic condition.
Initial Steps in Addressing Nation’s Health Inequities
Health equity is achieved when everyone has a reasonable opportunity to be as healthy as possible.
Medications for Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in adults over age 60.
340B Drug Pricing Program Undermined by Restrictions
In recent years, the 340B Drug Pricing program has experienced discount restrictions.
Optimizing Treatment for Rare Chronic Autoimmune Disease Myasthenia Gravis
Rare diseases and orphan drugs continue to be at the forefront of novel development.
Patient Access Network (PAN) Foundation: Helping Underinsured Patients with Rare Diseases Access Treatment and Medications
The inability to pay for essential medical care is not just a significant problem for the uninsured.
National Organization for Rare Diseases (NORD): Helping Patients Access Safe, Affordable Care and Medication
Now more than ever, rare disease patients need seamless access to care in order to comply with highly specialized treatment and maintain optimal health.
Navigating JAK Inhibitor Warnings
Janus kinase (JAK) inhibitors help ease joint pain and swelling in patients with rheumatoid arthritis.